Thursday November 26 2009 | Biotechnology feed | All feeds
|
|
Anacor Pharmaceuticals, Inc
Download detailed PDF Members: We have synthesized a class of compounds with characteristics that make them especially attractive for the topical treatment of onychomycosis. In particular, AN2690 penetrates the nail 200 times better than the only U.S. Food and Drug Administration-approved topical onychomycosis treatment. AN2690 potently inhibits Trichophyton rubrum and Trichophyton mentagrophytes, which are the two major fungi that cause onychomycosis.
This page has been viewed 445 times since April 2007, the link to the organisation's website has been followed 83 times Recent Search Terms used to find this page: quote anacor pharmaceuticals | Anacor Pharmaceuticals Inc | anacor | anacor logo | Search anacor | patent anacor | anacor yahoo | anacor pharmaceuticals | anacor patent | anacor patent | . Search for more companies in Palo Alto Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Anacor Pharmaceuticals, Inc | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|